TP53 and breast cancer: A better OS was observed in TP53 wild-type breast cancer patients with high EPB41L4A-AS2 expression, while the converse was found for breast cancer patients with a TP53 mutation (p < 0.01 and p = 0.43, respectively; Figure 3B and Supplementary Figure S8).